(Bloomberg) — The head of BioNTech SE, the German company that developed the first Covid-19 vaccine, said a new formula is likely to be needed by mid-2022 to protect against future mutations of the virus. Ugur Sahin, co-founder and chief executive officer of BioNtech, told the Financial Times that while current variants of Covid-19, such as the contagious delta strain, were not different enough to undermine current vaccinations, new strains will emerge that can evade booster shots and the body’
https://www.bloombergquint.com/business/biontech-ceo-says-new-covid-vaccines-will-be-needed-in-2022-ft
BioNTech CEO Says New Covid Vaccines Will Be Needed in 2022: FT
